Elanco Animal Health Incorporated (ELAN)
NYSE: ELAN · Real-Time Price · USD
22.30
+0.21 (0.95%)
At close: Dec 19, 2025, 4:00 PM EST
22.38
+0.08 (0.36%)
After-hours: Dec 19, 2025, 7:30 PM EST
Elanco Animal Health Stock Forecast
Stock Price Forecast
The 9 analysts that cover Elanco Animal Health stock have a consensus rating of "Buy" and an average price target of $23.11, which forecasts a 3.63% increase in the stock price over the next year. The lowest target is $18 and the highest is $30.
Price Target: $23.11 (+3.63%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Elanco Animal Health stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 3 | 3 | 3 | 4 | 5 | 6 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 8 | 9 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Maintains $18 → $22 | Hold | Maintains | $18 → $22 | -1.35% | Dec 18, 2025 |
| Barclays | Barclays | Buy Initiates $30 | Buy | Initiates | $30 | +34.53% | Dec 9, 2025 |
| Keybanc | Keybanc | Buy Initiates $27 | Buy | Initiates | $27 | +21.08% | Nov 21, 2025 |
| UBS | UBS | Strong Buy Maintains $25 → $27 | Strong Buy | Maintains | $25 → $27 | +21.08% | Nov 6, 2025 |
| UBS | UBS | Strong Buy Maintains $19 → $25 | Strong Buy | Maintains | $19 → $25 | +12.11% | Oct 20, 2025 |
Financial Forecast
Revenue This Year
4.76B
from 4.44B
Increased by 7.19%
Revenue Next Year
5.01B
from 4.76B
Increased by 5.32%
EPS This Year
0.95
from 0.68
Increased by 40.25%
EPS Next Year
1.05
from 0.95
Increased by 9.93%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 5.0B | 5.3B | ||||
| Avg | 4.8B | 5.0B | ||||
| Low | 4.5B | 4.7B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 11.8% | 10.5% | ||||
| Avg | 7.2% | 5.3% | ||||
| Low | 1.8% | -0.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 1.10 | 1.17 | ||||
| Avg | 0.95 | 1.05 | ||||
| Low | 0.88 | 0.96 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 62.1% | 22.2% | ||||
| Avg | 40.3% | 9.9% | ||||
| Low | 29.7% | 0.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.